News & Updates

Treatment of symptomatic COVID-19 with nirmatrelvir/ritonavir in children at least 6 years of age who are at risk of progression to severe disease appears to be safe and well-tolerated, with pharmacokinetic data from the open-label phase 2/3 EPIC-Peds* study indicating suitable dosing regimens for two distinct weight categories of this population.

Meeting the recommended hours of sleep per night appears to put adolescents at lower risk of hypertension, according to a study.

Fecal microbiota transplantation (FMT) can complement the use of retrograde colonic enema (RCE) in the treatment of children with intractable constipation, suggests a study.